AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35576384 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (intravenous ertapenem followed by oral levofloxacin and metronidazole)
Number of subjects: 72
Study 35576384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 35576502 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0
Study 35576502 — intervention group
Group type: COMPARATOR
Intervention: Open abdominal surgery
Number of subjects: 0
Study 35576508 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus nivolumab (paclitaxel 200 mg/m2)
Number of subjects: 0
Study 35576508 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus nivolumab
Number of subjects: 0
Study 35576529 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitapivat (AG-348) 50 mg BID
Number of subjects: 16
Study 35576529 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitapivat (AG-348)
Number of subjects: 16
Study 35576565 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app Malo
Number of subjects: 4000
Study 35576566 — intervention group
Group type: EXPERIMENTAL
Intervention: Micodigest 2.0
Number of subjects: 144
Study 35576566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 35576569 — intervention group
Group type: EXPERIMENTAL
Intervention: Step Away app
Number of subjects: 150
Study 35576569 — intervention group
Group type: EXPERIMENTAL
Intervention: Step Away chatbot
Number of subjects: 150
Study 35576569 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 150
Study 35576573 — intervention group
Group type: EXPERIMENTAL
Intervention: i♥rhythm intervention
Number of subjects: 40
Study 35576573 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 40
Study 35576575 — intervention group
Group type: EXPERIMENTAL
Intervention: OWL-H eHealth platform with teaching kitchen medical group visits (TKMGVs)
Number of subjects: 25
Study 35576863 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN model-based motion compensation method
Number of subjects: 1690
Study 35576863 — intervention group
Group type: COMPARATOR
Intervention: Tracking of the rapid pacing catheter tip with CC
Number of subjects: 1690
Study 35576960 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax plus ruxolitinib (navitoclax orally administered at 50 mg per day, escalated weekly to a maximum of 300 mg per day)
Number of subjects: 34
Study 35576960 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax plus ruxolitinib
Number of subjects: 34
Study 35577100 — intervention group
Group type: EXPERIMENTAL
Intervention: FFA clearance in people with obesity during hyperinsulinemic-euglycemic clamp procedure
Number of subjects: 60
Study 35577100 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 60
Study 35577100 — intervention group
Group type: EXPERIMENTAL
Intervention: FFA kinetics during basal conditions
Number of subjects: 60
Study 35577503 — intervention group
Group type: EXPERIMENTAL
Intervention: Emactuzumab (1000 mg) + Atezolizumab (1200 mg)
Number of subjects: 221
Study 35577536 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Step-by-Step intervention
Number of subjects: 680
Study 35577536 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care as usual (ECAU)
Number of subjects: 680
Study 35577814 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible insulin therapy (FIT) with heart rate sensors and automated closed insulin loop
Number of subjects: 0
Study 35578270 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive interventions (hospital death, anti-cancer treatment, more than 14 days in hospital, more than one hospital admission, more than one emergency room visit, at least one ICU admission)
Number of subjects: 345
Study 35578270 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive interventions
Number of subjects: 345
Study 35578270 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervening early in the sub-group of patients with history of hospitalization
Number of subjects: 345
Study 35578398 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent significant life-events (defined as changes in schooling/employment, residence, partnerships, sickness, incarceration status, family strife or death, and birth/pregnancy, self-reported alcohol use, being a parent, and HIV-status disclosure)
Number of subjects: 995
Study 35578398 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent significant life-events
Number of subjects: 995
Study 35578615 — intervention group
Group type: EXPERIMENTAL
Intervention: Granola with low beta-glucan (0.8 g)
Number of subjects: 14
Study 35578615 — intervention group
Group type: EXPERIMENTAL
Intervention: Granola with medium beta-glucan (3.2 g)
Number of subjects: 14
Study 35578615 — intervention group
Group type: EXPERIMENTAL
Intervention: Granola with high beta-glucan (6.6 g)
Number of subjects: 14
Study 35578615 — intervention group
Group type: EXPERIMENTAL
Intervention: Granola with beta-glucan (various amounts)
Number of subjects: 14
Study 35578615 — intervention group
Group type: COMPARATOR
Intervention: Control (200 ml low-fat milk)
Number of subjects: 14
Study 35578807 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic metformin treatment with aerobic training (EXER+MET)
Number of subjects: 63
Study 35578807 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training without metformin (EXER)
Number of subjects: 63
Study 35578807 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic metformin treatment
Number of subjects: 63
Study 35579010 — intervention group
Group type: EXPERIMENTAL
Intervention: Early revascularization
Number of subjects: 1000
Study 35579010 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive management
Number of subjects: 1000
Study 35579040 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-high severe asthma (n=17)
Number of subjects: 86
Study 35579040 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-intermediate severe asthma (n=21)
Number of subjects: 86
Study 35579040 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-low severe asthma (n=20)
Number of subjects: 86
Study 35579040 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=28)
Number of subjects: 86
Study 35579040 — intervention group
Group type: EXPERIMENTAL
Intervention: All asthma groups
Number of subjects: 86
Study 35579096 — intervention group
Group type: EXPERIMENTAL
Intervention: Constitutionally thin individuals (CT) during overfeeding
Number of subjects: 63
Study 35579096 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight individuals (control) during overfeeding
Number of subjects: 63
Study 35579382 — intervention group
Group type: COMPARATOR
Intervention: Multimodal physiotherapy
Number of subjects: 1339
Study 35579486 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication iatrogenic assessment using Trivalle score
Number of subjects: 100
Study 35579486 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPP criteria assessment
Number of subjects: 100
Study 35579486 — intervention group
Group type: EXPERIMENTAL
Intervention: START criteria assessment
Number of subjects: 100
Study 35579486 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of potentially inappropriate medications
Number of subjects: 100
Study 35579486 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of benzodiazepine prescriptions
Number of subjects: 100
Study 35579486 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of anticholinergic prescriptions
Number of subjects: 100
Study 35579509 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CCP)
Number of subjects: 180
Study 35579509 — intervention group
Group type: COMPARATOR
Intervention: Control plasma
Number of subjects: 180
Study 35579519 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphysema progression (Fleischner grading system)
Number of subjects: 5056
Study 35579519 — intervention group
Group type: COMPARATOR
Intervention: Nonprogressive emphysema
Number of subjects: 5056
Study 35579690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation (CPR)
Number of subjects: 0
Study 35579731 — intervention group
Group type: EXPERIMENTAL
Intervention: KX2-391 120 mg
Number of subjects: 24
Study 35579731 — intervention group
Group type: EXPERIMENTAL
Intervention: KX2-391 160 mg
Number of subjects: 24
Study 35579731 — intervention group
Group type: EXPERIMENTAL
Intervention: KX2-391 140 mg
Number of subjects: 24
Study 35579731 — intervention group
Group type: EXPERIMENTAL
Intervention: KX2-391
Number of subjects: 24
Study 35579840 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Dose (MD) of MVC-COV1901
Number of subjects: 45
Study 35579840 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose (HD) of MVC-COV1901
Number of subjects: 45
Study 35579840 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose (LD) of MVC-COV1901
Number of subjects: 45
Study 35579840 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of MVC-COV1901
Number of subjects: 45
Study 35579840 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of MVC-COV1901
Number of subjects: 45
Study 35579862 — intervention group
Group type: EXPERIMENTAL
Intervention: Naxitamab in combination with granulocyte-macrophage colony-stimulating factor
Number of subjects: 0
Study 35579862 — intervention group
Group type: EXPERIMENTAL
Intervention: Naxitamab
Number of subjects: 0
Study 35579915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual assault prevention intervention
Number of subjects: 31
Study 35579928 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual environment intervention for CVD prevention education
Number of subjects: 80
Study 35579928 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 80
Study 35579931 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Parent-Based Intervention (PBI)
Number of subjects: 100
Study 35579931 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 35579938 — intervention group
Group type: EXPERIMENTAL
Intervention: Low myocardial ATP levels
Number of subjects: 0
Study 35579938 — intervention group
Group type: COMPARATOR
Intervention: Normal ATP levels
Number of subjects: 0
Study 35580123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively-Based Compassion Training
Number of subjects: 0
Study 35580123 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35580141 — intervention group
Group type: EXPERIMENTAL
Intervention: SCRI-CAR19v2
Number of subjects: 21
Study 35580141 — intervention group
Group type: COMPARATOR
Intervention: SCRI-CAR19v1
Number of subjects: 21
Study 35580160 — intervention group
Group type: EXPERIMENTAL
Intervention: ESE plus lung ultrasound (4-site simplified scan)
Number of subjects: 4392
Study 35580160 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n=103)
Number of subjects: 4392
Study 35580298 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA detected in serum
Number of subjects: 50
Study 35580298 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA detected in urine
Number of subjects: 50
Study 35580298 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between serum ctDNA detection and tumor sequencing results
Number of subjects: 50
Study 35580298 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-free survival (EFS) in patients with ctDNA detected in serum
Number of subjects: 50
Study 35580298 — intervention group
Group type: COMPARATOR
Intervention: Event-free survival (EFS) in patients without ctDNA detected in serum
Number of subjects: 50
Study 35580314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 0
Study 35580913 — intervention group
Group type: EXPERIMENTAL
Intervention: Prereferral rectal artesunate (RAS)
Number of subjects: 2104
Study 35580970 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist management in 10 long COVID clinics across the UK
Number of subjects: 5000
Study 35580970 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-management at home with technology-supported monitoring
Number of subjects: 5000
Study 35580970 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalist management in primary care using electronic record data
Number of subjects: 5000
Study 35581305 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise (4×4-min intervals at 90-95% of maximal heart rate)
Number of subjects: 0
Study 35581305 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 35581464 — intervention group
Group type: EXPERIMENTAL
Intervention: DiamondTemp Ablation (DTA) RF generator
Number of subjects: 60
Study 35581627 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg t-PA with 5 mg DNase administered over 24 h
Number of subjects: 30
Study 35581637 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic FDG-PET (Patlak analysis)
Number of subjects: 30
Study 35581637 — intervention group
Group type: COMPARATOR
Intervention: Static FDG-PET
Number of subjects: 30
Study 35581637 — intervention group
Group type: COMPARATOR
Intervention: Dynamic FDG-PET (other kinetic models)
Number of subjects: 30
Study 35582784 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (1 Hz over the right dorsolateral prefrontal cortex)
Number of subjects: 38
Study 35583175 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/XDR for pulmonary tuberculosis detection
Number of subjects: 1228
Study 35583175 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/XDR for isoniazid resistance detection
Number of subjects: 1228
Study 35583175 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/XDR for fluoroquinolone resistance detection
Number of subjects: 1228
Study 35583175 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/XDR for ethionamide resistance detection
Number of subjects: 1228
Study 35583175 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/XDR for amikacin resistance detection
Number of subjects: 1228
Study 35583185 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-fluorocholine (18FCH) PET/CT
Number of subjects: 107
Study 35583798 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with ATTRwt amyloidosis
Number of subjects: 1386
Study 35583798 — intervention group
Group type: COMPARATOR
Intervention: Males with ATTRwt amyloidosis
Number of subjects: 1386
Study 35583828 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF_CEA
Number of subjects: 54
Study 35583828 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF_ctDNA
Number of subjects: 54
Study 35583828 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF_CEA combined with CSF_ctDNA
Number of subjects: 54
Study 35583828 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF_ctDNA for LM patients with hydrocephalus
Number of subjects: 54
Study 35584346 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body ER imaging with 16α-[
Number of subjects: 200
Study 35584349 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily
Number of subjects: 23
Study 35584850 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID participants (ever-COVID)
Number of subjects: 85
Study 35584850 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID participants (ever-hospitalised)
Number of subjects: 85
Study 35584870 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal inoculation with maternal respiratory microbiota
Number of subjects: 20
Study 35584876 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic individuals
Number of subjects: 751
Study 35584876 — intervention group
Group type: EXPERIMENTAL
Intervention: Low oxygen levels on enrolment
Number of subjects: 751
Study 35584876 — intervention group
Group type: EXPERIMENTAL
Intervention: More than one chronic comorbidity
Number of subjects: 751
Study 35584876 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, low oxygen level, respiratory symptoms, chronic comorbidities
Number of subjects: 751
Study 35584876 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 751
Study 35584875 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 hospitalised individuals
Number of subjects: 149
Study 35584910 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy for emergent large vessel occlusion
Number of subjects: 270
Study 35584910 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients with a history of diabetes or hypertension, elevated pretreatment SBP, and failed reperfusion
Number of subjects: 270
Study 35585125 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 109
Study 35585125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 109
Study 35585125 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 109
Study 35585554 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate calorie intake (10-20 kcal/kg)
Number of subjects: 1172
Study 35585554 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate protein intake (0.8-1.2 g/kg)
Number of subjects: 1172
Study 35585554 — intervention group
Group type: COMPARATOR
Intervention: Low calorie intake (< 10 kcal/kg)
Number of subjects: 1172
Study 35585554 — intervention group
Group type: COMPARATOR
Intervention: Low protein intake (< 0.8 g/kg)
Number of subjects: 1172
Study 35585554 — intervention group
Group type: COMPARATOR
Intervention: High calorie intake (> 20 kcal/kg)
Number of subjects: 1172
Study 35585554 — intervention group
Group type: COMPARATOR
Intervention: High protein intake (> 1.2 g/kg)
Number of subjects: 1172
Study 35585684 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination
Number of subjects: 0
Study 35585684 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated)
Number of subjects: 0
Study 35585781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients (betaine)
Number of subjects: 129
Study 35585781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients (TMAO)
Number of subjects: 129
Study 35585781 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-liver transplantation (betaine)
Number of subjects: 129
Study 35585781 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-liver transplantation (TMAO)
Number of subjects: 129
Study 35585781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients (CPT stage and MELD score)
Number of subjects: 129
Study 35585781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients (TMAO and MELD score)
Number of subjects: 129
Study 35585781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients (mortality)
Number of subjects: 129
Study 35585867 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Electromagnetic Treatment (TEMT)
Number of subjects: 8
Study 35587165 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 0
Study 35587172 — intervention group
Group type: COMPARATOR
Intervention: Topical clonidine (TC) 0.1% or 0.2% applied in gel form to the painful area two to three times daily for 8 to 12 weeks.
Number of subjects: 743
Study 35587370 — intervention group
Group type: COMPARATOR
Intervention: Standard PrEP counseling (Control)
Number of subjects: 160
Study 35587370 — intervention group
Group type: EXPERIMENTAL
Intervention: MES-PrEP and standard PrEP counseling
Number of subjects: 160
Study 35587370 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced YaCool and standard PrEP counseling
Number of subjects: 160
Study 35587370 — intervention group
Group type: EXPERIMENTAL
Intervention: MES-PrEP, Enhanced YaCool, and standard PrEP counseling
Number of subjects: 160
Study 35587408 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Identity Treatment (AIT)
Number of subjects: 60
Study 35587408 — intervention group
Group type: COMPARATOR
Intervention: Dialectical Behavior Therapy for Adolescents (DBT-A)
Number of subjects: 60
Study 35587446 — intervention group
Group type: EXPERIMENTAL
Intervention: binimetinib plus ribociclib
Number of subjects: 0
Study 35587487 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (4.5 mg/m2 daily for 7 days)
Number of subjects: 14
Study 35587487 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 14
Study 35587536 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic-dose subcutaneous enoxaparin (40 mg once daily) for 6 months after 3 months of therapeutic-dose LMWH.
Number of subjects: 52
Study 35587650 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix (by mouth once daily)
Number of subjects: 930
Study 35587650 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide (injected every 3 months)
Number of subjects: 930
Study 35587650 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix
Number of subjects: 930
Study 35587650 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 930
Study 35587832 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-to-peer training and follow-up academic detailing including overdose prevention education and buprenorphine prescribing.
Number of subjects: 122
Study 35588104 — intervention group
Group type: EXPERIMENTAL
Intervention: Glabellar onabotulinumtoxinA injections
Number of subjects: 9
Study 35588166 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics (AB+)
Number of subjects: 436
Study 35588166 — intervention group
Group type: EXPERIMENTAL
Intervention: Food allergy
Number of subjects: 436
Study 35588166 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 436
Study 35588252 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation (four-week trimodal programme: exercise, nutritional intervention, anxiety reduction)
Number of subjects: 250
Study 35588252 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 250
Study 35588274 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified fluid gelatin 4% in a balanced electrolyte solution
Number of subjects: 221
Study 35588274 — intervention group
Group type: COMPARATOR
Intervention: Albumin (50 g L)
Number of subjects: 221
Study 35588317 — intervention group
Group type: EXPERIMENTAL
Intervention: Idursulfase-IT 10 mg or 30 mg administered monthly via IT drug delivery device or lumbar puncture
Number of subjects: 15
Study 35588317 — intervention group
Group type: EXPERIMENTAL
Intervention: Idursulfase-IT treatment
Number of subjects: 15
Study 35588372 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of AKI within 72 hours after surgery according to KDIGO criteria
Number of subjects: 10000